DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* THERADIAG *


 

1987 - IDF
Marne-la-Vallée
(near Paris)
www.theradiag.com

 

Discovery, Diagnostics
(also, Design, Devices)
Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex
Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases
Clients: Pharmaceutical industry
info@theradiag.com

Age: 30 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Finance (Michel) [Ms. EM Lyon, ex-Neovacs, Carmat, Flamel Technologies, Aventis]
Tech.Dir.-CTO: Parussini (Ermis), Ms.Sc. molecular biology, ex-Biomérieux
Sc.Dir.-CSO:
Sales Dir.: Sallen (Eric), Abbott, Becton Dickinson, Saint Gobain, Kottermann, Seroa]
Admin.Dir.: François (Fabienne) [MBA, HR experience]
BusDev:
Financers (Hist.): Truffle Venture (majority share), CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova
Communication:with company name change, the URL moves and www.bmd-net.com is deleted (June 2012)

Turnover (M€) : 11.25 (2009), 12.22 (2008), 15.6 (2006)
Total funding (M€) : 11.2
Last funding (M€) : 8.2
Focus : Allergy
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2013 .04 Financing (no interest loan) : 1.2 M€ from OSEO Innovation (on 4 new diagnostic test within the 18 M€ project labelled CaReNa) DEBT [26 years]
2012 .12 Listing on Euronext : 8.2 M€ (IPO), extended to 8.6 M€ in January 2013 PBO [25 years]
2012 .07 Acquisition of Prestizia and its microRNA technology platform (presided by Jean-Jacques Bertrand) ACQ+ [25 years]
2012 .05 Company rename as Theradiag (from BioMedical Diagnostics or BMD) with no change in capital structure ORGL [25 years]
2011 .01 Nomination : Michel Finance as CEO (replacing Paul Magrez) ORGN [23 years]
2010 .03 Partnering distribution agreement from Assuragen (USA) to commercialize its Signature Oncology Products in France MKTG [23 years]
2009 .12 4th round-financing : 3.0 M€ by Truffle Venture and AGF P.E. RFIND [22 years]
2008 .10 Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), OSEO Innovation, to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics DEBT [21 years]
2007 .00 Nomination : Paul Magrez, as CEO (replacing Patrick G. Poty) ORGN [19 years]
2005 .07 3rd round-financing : 5.0 M€, led by Truffle Venture and CDC Entreprise, with AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova RFINC [18 years]
2004 .05 Nomination : Patrick G. Poty, as CEO (Daniel Pierron on leave) ORGN [17 years]
2003 .05 2nd round-financing : 9.4 M€, by undisclosed investors RFINB [16 years]
2000 .05 1st round-financing : 4.6 M€, by undisclosed investors RFINA [13 years]
1987 .02 Company founded by 2 ex-Abbott managers, as BioMedical Diagnostics ORGF [0 year]

Actualisation / Updating: 19-Apr-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende